ArticleMovement disorders : official journal of the Movement Disorder Society2023
Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants.
Article in Movement disorders : official journal of the Movement Disorder Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Classification and Genotype-Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2025Pooled it
- Does genetic testing remain relevant in advanced Parkinson's disease?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation.Annals of neurology · 2026Article
- Proceedings of the 13th annual deep brain stimulation think tank: the evolving landscape.Frontiers in human neuroscience · 2026Review
- Predicting cognition after subthalamic Deep Brain Stimulation in Parkinson's Disease.NPJ Parkinson's disease · 2025Article
- Deep Brain Stimulation Improves Symptoms in an Individual with Alpha-Synuclein-Gene-Associated Parkinson's Disease.Movement disorders clinical practice · 2025Article
- Acute Neuropsychiatric Decline in a Parkinson's Disease Patient with a Severe GBA1 Mutation Following Bilateral GPi Deep Brain Stimulation.Movement disorders clinical practice · 2025Article
- Serum glial fibrillary protein reflects early brain injury dynamics and cognitive changes after deep brain stimulation surgery.Scientific reports · 2025Article
- The impact of mild-to-moderate cortical cognitive deficits on post-operative outcomes in deep brain stimulation for Parkinson's disease: Considerations for patient selection.Clinical parkinsonism & related disorders · 2025Article
- A meta-analysis of the effects of DBS on cognitive function in patients with advanced PD.Open medicine (Warsaw, Poland) · 2025Review
- Atrophy-related corticospinal changes in advanced Parkinson's disease are associated with the genetic etiology of the disease.Journal of Parkinson's disease · 2024Article
- New Perspectives of Deep Brain Stimulation Indications for Parkinson's Disease: A Critical Review.Brain sciences · 2024Review
- Effects of STN-DBS on cognition and mood in young-onset Parkinson's disease: a two-year follow-up.Frontiers in aging neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Genetic subtyping of patients with Parkinson's disease (PD) may assist in predicting the cognitive and motor outcomes of subthalamic deep brain stimulation (STN-DBS). Practical questions were recently raised with the emergence of new data regarding suboptimal cognitive outcomes after STN-DBS in individuals with PD associated with pathogenic variants in glucocerebrosidase gene (GBA1-PD). However, a variety of gaps and controversies remain. (1) Does STN-DBS truly accelerate cognitive deterioration in GBA1-PD? If so, what is the clinical significance of this acceleration? (2) How should the overall risk-to-benefit ratio of STN-DBS in GBA1-PD be established? (3) If STN-DBS has a negative effect on cognition in GBA1-PD, how can this effect be minimized? (4) Should PD patients be genetically tested before STN-DBS? (5) How should GBA1-PD patients considering STN-DBS be counseled? We aim to summarize the currently available relevant data and detail the gaps and controversies that exist pertaining to these questions. In the absence of evidence-based data, all authors strongly agree that clinicians should not categorically deny DBS to PD patients based solely on genotype (GBA1 status). We suggest that PD patients considering DBS may be offered genetic testing for GBA1, where available and feasible, so the potential risks and benefits of STN-DBS can be properly weighed by both the patient and clinician. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.